About Multiplier AI IPO
The Multiplier AI IPO is a book-built issue comprising a fresh issue of up to 35 lakh equity shares, with a face value of ₹10 per share. The company filed its DRHP with SEBI on February 27, 2025. The price band and official dates of subscription and listing will be announced by the company later, but the equity shares are supposed to be listed on the NSE Emerge platform. This issue will be managed by Swastika Investmart Ltd. as the Book Running Lead Manager (BRLM), while MUFG Intime India Private Ltd. is acting as the registrar to the offer.
Company Background
Multiplier AI Ltd. was incorporated as a partnership firm in 2011, which was later converted to a private limited company in 2016 and finally registered with the name Multiplier AI Ltd. in 2024. The current business activity of the company is entirely devoted to providing artificial intelligence (AI) solutions and digital transformation strategies to the pharmaceutical and healthcare industries. The corporate office of the company is located in Madhapur, Hyderabad, Telangana, with another branch office in Noida, Uttar Pradesh, to maintain its presence in the domestic as well as global market.
Operations & Product Range
Multiplier AI Ltd. is a technology and digital marketing services company specifically designed for the life sciences ecosystem. Its main services include proprietary AI solutions, such as the GenAI Doctor Data Platform and Patient Intelligence Platform and copilots using GPT and LLM technology, designed for pharmaceutical companies, medical device companies and hospital groups looking to improve their physician and patient acquisition strategy.
Facilities & Capacity
The operational execution of Multiplier AI Ltd. is primarily carried out from their corporate head office in Hyderabad and their branch facility in Noida. The ability of Multiplier AI Ltd. to deliver its complex data intelligence and marketing solutions is enabled by its professional workforce of 84 employees as of December 2024. This issue mainly focuses on increasing its operational execution by setting up new offices and specialized strategic teams in India and international markets.
Brands & Market Presence
Multiplier AI Ltd. is operating under the brand umbrella and is actively promoting its unique digital platforms, such as HCP IQ, to its enterprise clients. It has a good presence in the home market and is expanding its export market presence by servicing global life sciences organizations in the US, Europe and Southeast Asia markets. One of the biggest recognitions of its market presence is its partnership with and servicing of more than 30 of the top pharmaceutical companies worldwide.
Revenue Streams & Business Model
The main revenue sources for Multiplier AI Ltd. include the deployment and licensing of its artificial intelligence (AI)-based data analytics platforms, predictive modeling solutions and digital marketing campaigns. The financial contributions for Multiplier AI Ltd. come from both domestic operations and export business in the life sciences space globally.
The business model is focused on enabling healthcare businesses to adopt data-driven marketing strategies in place of conventional marketing practices, generating a total income of ₹11.65 Cr for FY24.
Management & Shareholding
The entire strategic vision and operational execution of Multiplier AI Ltd. are directed by its core promoters, namely Mr. Vikram Kumar and Ms. Saumya Prakash. The entire shareholding of 100% equity by the promoter group of Multiplier AI Ltd., before the Multiplier AI IPO, will undergo qualitative dilution after the IPO to accommodate the new public investors in the enhanced capital base of the organization.
Board & Key Management
The promoter group of Multiplier AI Ltd. is built with an experienced and expert CEO, Mr. Vikram Kumar, leading the charge in growing the business of Multiplier AI in the long term. The executive board is supplemented by key management personnel, such as their CFO, Ms. Saumya Prakash and their CS, Mr. Aakash Jaiswal, who also acts as their compliance officer, to ensure corporate governance, which is vital for the Multiplier AI IPO to be approved.
Multiplier AI IPO Details
| Detail | Description |
|---|---|
| IPO Date | - |
| Listing Date | - |
| Face Value | ₹ 10 per share |
| Issue Price Band | - |
| Lot Size | - |
| IPO Type | Fresh Capital |
| Total Issue Size | - |
| Reserved for Market Maker | - |
| Fresh Issue(Ex Market Maker) | Upto 35,00,000 Equity Shares aggregating to ₹ [●] Cr |
| Offer for Sale | - |
| Net Offered to Public | - |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 84,24,803 Shares |
| Share Holding Post Issue | - |
Multiplier AI IPO Financial Information
Latest Revenue
7.02
₹ Crore
Profit After Tax
3.24
₹ Crore
Net Worth
13.02
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 2024 | 17.16 | 7.02 | 3.24 | 13.02 | 4.60 | — | |||
| 31 Mar 2024 | 13.47 | 11.65 | 4.10 | 9.79 | 9.38 | — | |||
| 31 Mar 2023 | 11.85 | 15.75 | 1.33 | 5.68 | 5.28 | — | |||
| 31 Mar 2022 | 7.95 | 10.30 | 0.63 | 4.35 | 3.95 | — | |||
| Amount in ₹ Crore | |||||||||
Multiplier AI Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 41.90% |
| ROCE | - |
| Debt/Equity | - |
| RoNW | 41.90% |
| PAT Margin | 36.58% |
| EBITDA Margin | - |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 100% | - |
| P/E (x) | - | - |
IPO Objectives
The company intends to use the proceeds from the Multiplier AI IPO for its strategic purposes.
- • Funding the capital expenditures to upgrade existing infrastructure across domestic and international markets
- • Investing in the marketing and branding expenses to enhance visibility
- • General corporate expenses
Conclusion
The Multiplier AI IPO is a chance for investors to put their money in a company that emphasizes the importance of a focused approach to dealing with issues of inefficiencies in the pharmaceutical and life sciences industry through the provision of generative artificial intelligence solutions. By providing unique data analytics and specialized marketing solutions, the company is providing a unique solution for healthcare organizations that will improve their decision-making processes of the company. The company clearly aims to upgrade its infrastructure and expand its global team by implementing borderless digital markets through this IPO.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Proprietary Artificial Intelligence (AI) Agents and Generative Artificial Intelligence Tools Created Exclusively for the Healthcare and Pharmaceutical Industries
Comprehensive data assets that validate and enhance targeted physician and patient intelligence.
Established client relationships with leading global life sciences companies in various geographic markets.
| Sr.no | Description | Date | File |
|---|---|---|---|
| 1 | Filed with SEBI/Exchange | 25/02/2025 | - |
| 2 | SEBI/Exchange approval received | - | - |
Multiplier AI IPO Timeline
| IPO Open Date | - |
| IPO Close Date | - |
| Tentative Allotment | - |
| Initiation of Refunds | - |
| Credit of Shares to Demat | - |
| Tentative Listing Date | - |
| Cut-off time for UPI mandate confirmation | - |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | — | — | |
| Individual investors (Retail) (Max) | — | — | |
| S-HNI (Min) | — | — | |
| S-HNI (Max) | — | — | |
| B-HNI (Min) | — | — |